IVIG Dose Calculator - Calculate Immunoglobulin Dosing
Calculate Intravenous Immunoglobulin (IVIG) doses in grams and milliliters (mL). Automatically compares Actual Body Weight, Devine Ideal Body Weight (IBW), and Adjusted Body Weight (AdjBW).
Interactive IVIG Dose Calculator
AAAAI & FDA Stewardship EquationsIVIG Regimen Output
LiveWhat Is an IVIG Dose Calculator?
An IVIG dose calculator is a clinical pharmacy and immunology dosing tool used to determine the appropriate mass (grams) and infusion volume (milliliters) of Intravenous Immunoglobulin (IVIG) for replacement and immunomodulatory therapy. Pooled human immunoglobulin G (IgG) is fractionated from donor plasma and represents a limited-supply biologic agent with a narrow hemodynamic and renal safety margin. When hospital pharmacists evaluate patients with elevated adiposity across hydrophilic drug classes, cross-checking anthropometrics with an adjusted weight calculator standardizes pharmacy stewardship.
Unlike small-molecule lipophilic medications that partition broadly into peripheral fat stores, IgG antibodies are large polar glycoproteins (~150 kDa) restricted primarily to the intravascular plasma compartment and interstitial extracellular fluid. Administering IVIG based on unadjusted Actual Body Weight (ABW) in overweight or obese patients delivers supratherapeutic intravascular IgG concentrations without increasing tissue efficacy.
According to clinical practice parameters established by the American Academy of Allergy, Asthma & Immunology (AAAAI), immunoglobulin dosing must be individualized by indication, body composition, baseline renal function, and post-infusion IgG trough monitoring. By comparing Actual Body Weight (ABW), Devine Ideal Body Weight (IBW), and Adjusted Body Weight (AdjBW), this calculator helps prevent hyperviscosity-induced thromboembolism, osmotic nephrosis, and biologic wastage.
How the IVIG Dosing & Adjusted Body Weight Formula Works
Clinical IVIG calculation follows a three-stage decision tree: computing Ideal Body Weight (IBW) from height and biological sex, evaluating whether Actual Body Weight exceeds the obesity threshold (ABW > 1.2 × IBW or BMI ≥ 30 kg/m²), and multiplying the selected dosing weight by the prescribed grams-per-kilogram (g/kg) regimen. Clinicians evaluating standalone anthropometric equations can also consult our ideal body weight calculator.
1. Devine IBW Equations
Female IBW = 45.5 + 2.3 × (Htin − 60)
Height in centimeters converts to inches via Htin = Htcm ÷ 2.54.
2. Adjusted Body Weight (AdjBW)
Total Dose (g) = Dosing Wt × Rate
Triggered when ABW > 1.2 × IBW or BMI ≥ 30. Standard CF = 0.4.
Consider an adult male with acute Immune Thrombocytopenia (ITP) weighing 110.0 kg at 180 cm (70.87 in), prescribed 1.0 g/kg with CF = 0.4:
- Devine IBW: 50 + 2.3 × (70.87 − 60) = 75.0 kg (120% threshold = 90.0 kg; BMI = 34.0 kg/m²)
- Adjusted Body Weight: 75.0 + 0.4 × (110.0 − 75.0) = 75.0 + 14.0 = 89.0 kg
- Total IVIG Dose: 89.0 kg × 1.0 g/kg = 89.0 grams (890 mL of 10% [100 mg/mL] solution, saving 21.0 g vs. ABW).
As reviewed in the NCBI StatPearls clinical monograph on Intravenous Immunoglobulin, pharmacokinetic studies confirm that AdjBW dosing with a 0.4 factor achieves equivalent area-under-the-curve (AUC) and trough IgG increments in obese patients compared to lean controls while preventing hyperviscosity complications.
Key Immunoglobulin Pharmacokinetic & Weight Concepts
Administering IVIG safely requires coordinating weight-based gram calculations with concentration-specific volumetric infusion rates. Once total milliliter volume is determined from the 5% or 10% bottle concentration, nursing staff program stepwise pump escalation schedules using an IV flow rate calculator.
Actual Body Weight (ABW)
Used when patient weight is ≤120% of Ideal Body Weight and BMI is under 30 kg/m².
Ideal Body Weight (IBW)
Estimates lean physiological mass from stature and sex. Floored at 30.0 kg for heights under 60 inches.
Adjusted Weight (AdjBW)
Accounts for the ~40% extracellular fluid expansion within excess adipose tissue, preventing intravascular IgG overload.
5% vs. 10% Formulations
A 10% IVIG solution contains 100 mg/mL (10 mL/g). A 5% IVIG solution contains 50 mg/mL (20 mL/g).
According to biologic standards regulated by the U.S. Food and Drug Administration (FDA) Immune Globulins portal, commercial IVIG preparations differ in osmolarity, sodium content, IgA trace levels, and stabilizers (L-proline, glycine, maltose, or D-sorbitol). Hospital pharmacies routinely round the calculated dose to the nearest commercial vial size (5 g or 10 g) within ±10% to prevent discarding human plasma derivatives.
How to Use the IVIG Dose Calculator in Clinical Practice
Follow these verification steps to determine the dosing weight, total gram regimen, and starting infusion rate. When gravity-fed secondary lines are verified at the bedside, clinicians can cross-check drop rates using our drip rate calculator.
- Select Biological Sex & Enter Anthropometrics: Choose Female or Male and input measured weight in kilograms (
kg) and standing height in centimeters (cm) to compute BMI and Devine IBW. - Enter Prescribed Dose Rate (g/kg): Input the ordered regimen (
0.4–0.6 g/kgfor Primary Immunodeficiency every 3–4 weeks,1.0 g/kgfor acute ITP, or2.0 g/kgtotal course for Guillain-Barré syndrome, CIDP induction, or Kawasaki disease). - Select Institutional Correction Factor (CF): Choose
0.4(standard stewardship protocol) or0.5per hospital P&T committee policy. - Verify Dosing Weight & Vial Rounding: Review whether Actual or Adjusted Body Weight applies, round to the nearest 5 g or 10 g commercial vial increment, and divide multi-day courses (e.g., 0.4 g/kg/day × 5 days or 1.0 g/kg/day × 2 days).
Clinical Indications, Dosing Regimens & Infusion Rate Protocols
Evidence-based IVIG dosing balances Fc-receptor saturation against hemodynamic volume load. In critical care or hematology settings where patients require coagulation factor replacement, clinicians can evaluate plasma volume requirements with our fresh frozen plasma dose calculator.
| Indication | Total Dose | Schedule / Split | Clinical Target / Notes |
|---|---|---|---|
| Primary Immunodeficiency | 0.4 – 0.6 g/kg | Single dose q3–4 wks | Maintain trough IgG ≥ 700–800 mg/dL |
| Immune Thrombocytopenia | 1.0 – 2.0 g/kg | 1 g/kg × 1–2 days | Second dose if platelets < 30,000/μL |
| Guillain-Barré Syndrome | 2.0 g/kg total | 0.4 g/kg/day × 5 days | 5-day split preferred over 2-day |
| CIDP (Induction / Maint.) | 2.0 / 1.0 g/kg | Over 2–5d, then q3w | Induction 2 g/kg; maint. 1 g/kg q3w |
| Myasthenia Gravis Crisis | 1.0 – 2.0 g/kg | 0.4 g/kg/day × 5 days | 1.0 g/kg single-day in mild flare |
| Kawasaki Disease | 2.0 g/kg total | Single 10–12 hr infusion | Give within 10 days of fever onset |
Stepwise Infusion Titration: For a 10% (100 mg/mL) IVIG formulation, infusions initiate at 0.5 to 1.0 mg/kg/min (0.3 to 0.6 mL/kg/hr) for 15 to 30 minutes, then double every 15 to 30 minutes as tolerated up to product ceilings (capped at ≤ 2.0 to 3.3 mg/kg/min in patients with renal or thrombotic risk factors).
Clinical Risk Factors, Boxed Warnings & Model Limitations
Prescribers and infusion nurses must screen every patient for high-risk comorbidities prior to initiating IVIG therapy:
- FDA Boxed Warning – Thrombosis: Arterial and venous thromboembolic events can occur during or after IVIG infusion due to hyperviscosity and trace Factor XIa. Risk factors include age >65 years, immobilization, hypercoagulable states, central catheters, and rapid high-dose infusions. Pre-hydrate and use Adjusted Body Weight in obesity.
- FDA Boxed Warning – Renal Dysfunction: Acute kidney injury and osmotic nephrosis occur most frequently with sucrose-stabilized products and in patients with pre-existing CKD, diabetes, volume depletion, or nephrotoxic drugs. Select sucrose-free formulations (proline or glycine) and slow infusion rates.
- Selective IgA Deficiency: Patients with severe IgA deficiency (<7 mg/dL) and anti-IgA antibodies risk anaphylaxis; select IgA-depleted IVIG or subcutaneous immunoglobulin (SCIG).
- Maltose Glucometer Interference: Maltose-stabilized IVIG cross-reacts with GDH-PQQ glucose test strips, causing falsely elevated blood sugar readings; verify glucose using glucose-specific laboratory methods.
- Aseptic Meningitis, Hemolysis & TRALI: High-dose IVIG (1–2 g/kg) carries risks of aseptic meningitis, isohemagglutinin hemolysis (in blood types A, B, AB), and Transfusion-Related Acute Lung Injury (TRALI).
Frequently Asked Questions (FAQ)
Q: How is the Intravenous Immunoglobulin (IVIG) dose calculated?
A: The total IVIG dose in grams is calculated by multiplying the patient's selected clinical dosing weight in kilograms (kg) by the prescribed indication dose rate in grams per kilogram (g/kg). For non-obese patients, Actual Body Weight (ABW) is used. For patients whose actual weight exceeds 120% of Ideal Body Weight (IBW) or whose Body Mass Index (BMI) is 30 kg/m² or higher, institutional stewardship guidelines recommend using Adjusted Body Weight (AdjBW).
Q: Why is Adjusted Body Weight (AdjBW) used for IVIG dosing in obesity?
A: Human Immunoglobulin G (IgG) is a large, polar macromolecule (molecular weight ~150 kDa) with a small volume of distribution (roughly 0.07 to 0.14 L/kg) that remains confined primarily to the intravascular plasma volume and extracellular fluid space rather than penetrating poorly vascularized adipose tissue. Dosing obese patients on unadjusted Actual Body Weight produces supratherapeutic serum IgG peaks that elevate blood viscosity and increase the risk of thromboembolism and acute kidney injury without improving clinical efficacy.
Q: What is the standard dose of IVIG for Primary Immunodeficiency (PI) versus autoimmune crises?
A: For humoral replacement therapy in Primary Immunodeficiency (PI), standard maintenance IVIG dosing ranges from 0.4 to 0.6 g/kg (400 to 600 mg/kg) administered intravenously every 3 to 4 weeks, titrated to maintain trough serum IgG levels above 700 to 800 mg/dL. Conversely, acute immunomodulatory indications—such as Immune Thrombocytopenia (ITP), Guillain-Barré syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), myasthenia gravis crisis, or Kawasaki disease—typically require 1.0 to 2.0 g/kg divided over 2 to 5 consecutive days.
Q: How does the Devine formula calculate Ideal Body Weight (IBW) for IVIG stewardship?
A: The Devine equation computes Ideal Body Weight (IBW) from patient height and biological sex. For adult males, IBW (kg) = 50 + 2.3 × (Height in inches − 60). For adult females, IBW (kg) = 45.5 + 2.3 × (Height in inches − 60). Once IBW is established, Adjusted Body Weight is calculated as AdjBW = IBW + CF × (Actual Weight − IBW), where the Correction Factor (CF) is typically 0.4 (40% of excess adipose mass).
Q: How do you convert a calculated IVIG gram dose into milliliters (mL) for infusion?
A: Commercial liquid IVIG formulations are dispensed primarily as 10% solutions (100 mg/mL, or 0.1 g/mL) or 5% solutions (50 mg/mL, or 0.05 g/mL). For a standard 10% (100 mg/mL) formulation, multiply the total dose in grams by 10 to obtain the infusion volume in milliliters (e.g., 60 grams = 600 mL). For a 5% (50 mg/mL) formulation, multiply the total dose in grams by 20 (e.g., 60 grams = 1,200 mL).
Q: What are the FDA Boxed Warnings associated with IVIG administration?
A: All commercial IVIG products carry FDA Boxed Warnings for Thrombosis and Renal Dysfunction / Acute Renal Failure. Thrombosis may occur regardless of cardiovascular risk factors due to hyperviscosity and procoagulant trace factors (Factor XIa). Osmotic nephrosis and acute renal failure occur predominantly with sucrose-stabilized formulations and rapid infusion rates. Pre-infusion crystalloid hydration, slow initial infusion titration, and Adjusted Body Weight dosing mitigate these risks.